Report: Pipeline Insight: Cancer Overview - Breast, Gynecological, Genitourinary - Diverse drugs approaching the market for many tumor types TOC

ABOUT DATAMONITOR HEALTHCARE
- About the Oncology pharmaceutical analysis team
CHAPTER 1 EXECUTIVE SUMMARY
- Scope of the analysis
- Datamonitor insight into the cancer market
- Related reports
- Upcoming reports
CHAPTER 2 PIPELINE OVERVIEW AND DYNAMICS
- Pipeline overview
  - Late-phase pipeline
  - Pipeline by indication
    - Breast cancer and prostate cancer will always remain popular R&D targets, however, the niche indications are increasing in popularity
CHAPTER 3 R&D APPROACH
- Classification of pipeline products
  - Cytotoxics
  - Antihormonal therapies
  - Molecular targeted therapies
  - Immunotherapeutic agents
- Oncology clinical trial design
CHAPTER 4 BLADDER CANCER
- Overview of bladder cancer
  - Definition
    - Bladder cancer is a common tumor type in males
  - Epidemiology
    - Incidence of bladder cancer will rise due to an increase in industrialization, lifestyle factors and an ageing population
    - Mortality from bladder cancer is very low in the early stages, however, rises dramatically once the tumor spreads
  - Treatment of bladder cancer
- Unmet need in bladder cancer
  - Summary of unmet needs
    - Increase early diagnosis to enhance survival
    - Agents with better routes of administration in comparison with intravesical therapy
    - A better ' standard' for advanced disease with less toxicity is needed
    - Salvation of the bladder is the ideal
- Pipeline overview
  - Pipeline summary
  - Late-phase pipeline
  - Phase II pipeline
  - Comparative forecasts
  - Definition of current comparator therapy
- Pipeline candidates
  - Urocidin (MCC; Bioniche)
    - Drug overview
    - Key historical events
    - Clinical development in bladder cancer
    - Datamonitor comments
  - EOquin (apaziquone; Spectrum Pharmaceuticals)
    - Drug overview
    - Key historical events
    - Clinical development in bladder cancer
    - Datamonitor comments
  - Valstar (valrubicin; Indevus)
    - Drug overview
    - Key historical events
    - Clinical development in bladder cancer
    - Datamonitor comments
  - Larotaxel (XRP-9881; Sanofi-Aventis)
    - Drug overview
    - Key historical events
    - Clinical development in bladder cancer
    - Datamonitor comments
  - Satisfaction of unmet needs
    - Some satisfaction of unmet needs will occur, however, further research is needed in advanced disease
CHAPTER 5 BREAST CANCER
- Overview of breast cancer
  - Definition
    - Breast cancer remains the most common cancer and second most common cause of cancer-related death in women worldwide
  - Epidemiology
    - Incidence of breast cancer will continue to rise as lifestyles associated with risk factors are increasingly adopted and in line with the ageing population
    - While mortality rates are low in comparison to incidence, absolute mortality shows breast cancer remains a leading cause of death in women
  - Treatment of breast cancer
- Unmet need in breast cancer
  - Summary of unmet needs
    - Effective treatment for metastatic disease still remains elusive
    - A wider range of treatment options is necessary for hormone receptor-negative and HER-2 negative patients
    - Elderly patients remain underserved in terms of treatment options
    - More convenient and better tolerated therapies are needed
- Pipeline overview
  - Pipeline summary
  - Late-phase pipeline
  - Phase II pipeline
  - Comparative forecasts
  - Definition of current comparator therapy
- Pipeline candidates
  - Afinitor (everolimus; Novartis)
    - Drug overview
    - Key historical events
    - Clinical development in breast cancer
    - Datamonitor comments
  - Armala (pazopanib; GlaxoSmithKline)
    - Drug overview
    - Key historical events
    - Clinical development in breast cancer
    - Datamonitor comments
  - Omnitarg (pertuzumab; Genentech/Roche/Chugai)
    - Drug overview
    - Key historical events
    - Clinical development in breast cancer
    - Datamonitor comments
  - Sutent (sunitinib; Pfizer)
    - Drug overview
    - Key historical events
    - Clinical development in breast cancer
    - Datamonitor comments
  - Ramucirumab (IMC-1121B; ImClone)
    - Drug overview
    - Key historical events
    - Clinical development in breast cancer
    - Datamonitor comments
  - Eribulin (E7389; Eisai)
    - Drug overview
    - Key historical events
    - Clinical development in breast cancer
    - Datamonitor comments
  - Satisfaction of unmet needs
    - The four targeted therapies in late-phase development for breast cancer show promise in fulfilling some unmet need
CHAPTER 6 CERVICAL CANCER
- Overview of cervical cancer
  - Definition
    - Cervical cancer constitutes 17% of all gynecological tumors
  - Epidemiology
    - Incidence rates of cervical cancer have decreased due to screening programs, however overall incidence will rise in line with the ageing population
    - Mortality is relatively high in comparison to incidence of cervical cancer given its propensity for early diagnosis
  - Treatment of cervical cancer
- Unmet need in cervical cancer
  - Summary of unmet needs
    - Better systemic therapy is required for metastatic and recurrent disease
    - More large-scale, randomized clinical trials are necessary to define optimal treatment strategies across cervical cancer
    - The cervical cancer pipeline is relatively sparse
- Pipeline overview
  - Pipeline summary
  - Late-phase pipeline
  - Phase II pipeline
  - Comparative forecasts
  - Definition of current comparator therapy
- Pipeline candidates
  - Gemzar (gemcitabine; Eli Lilly)
    - Drug overview
    - Key historical events
    - Clinical development in cervical cancer
    - Datamonitor comments
  - Tirazone (tirapazamine; National Cancer Institute/Stanford University/SRI International)
    - Drug overview
    - Key historical events
    - Clinical development in cervical cancer
    - Datamonitor comments
  - Satisfaction of unmet needs
    - Unmet needs are unlikely to be fulfilled by the current pipeline
CHAPTER 7 OVARIAN CANCER
- Overview of ovarian cancer
  - Definition
    - Ovarian cancer is the most frequent cause of cancer-related death from gynecological malignancies
  - Epidemiology
    - Incidence of ovarian cancer will rise in line with the ageing population since it affects primarily postmenopausal women
    - Mortality from ovarian cancer is relatively high in comparison with its incidence due to a high rate of diagnosis at Stage III disease
  - Treatment of ovarian cancer
- Unmet need in ovarian cancer
  - Summary of unmet needs
    - Earlier rates of diagnosis are needed
    - Less invasive surgical techniques are required
    - More effective systemic therapies are needed across multiple lines of treatment
    - Increase level of R&D interest
- Pipeline overview
  - Pipeline summary
  - Late-phase pipeline
  - Phase II pipeline
  - Comparative forecasts
  - Definition of current comparator therapy
- Pipeline candidates
  - Avastin (bevacizumab; Genentech/Roche)
    - Drug overview
    - Key historical events
    - Clinical development in ovarian cancer
    - Datamonitor comments
  - Telcyta (canfosfamide; Telik)
    - Drug overview
    - Key historical events
    - Clinical development in ovarian cancer
    - Datamonitor comments
  - Phenoxodiol (Marshall Edwards)
    - Drug overview
    - Key historical events
    - Clinical development in ovarian cancer
    - Datamonitor comments
  - Karenitecin (cositecan; BioNumerik)
    - Drug overview
    - Key historical events
    - Clinical development in ovarian cancer
    - Datamonitor comments
  - Opaxio (paclitaxel poliglumex; Cell Therapeutics/Novartis)
    - Drug overview
    - Key historical events
    - Clinical development in ovarian cancer
    - Datamonitor comments
  - Yondelis (trabectedin; PharmaMar/Johnson & Johnson)
    - Drug overview
    - Key historical events
    - Clinical development in ovarian cancer
    - Datamonitor comments
  - Patupilone (EPO-906; Novartis)
    - Drug overview
    - Key historical events
    - Clinical development in ovarian cancer
    - Datamonitor comments
  - Abagovomab (ACA-125; Menarini/CellControl BioMedical)
    - Drug overview
    - Key historical events
    - Clinical development in ovarian cancer
    - Datamonitor comments
  - Satisfaction of unmet needs
    - Unmet needs in ovarian cancer will be fulfilled to some extent by means of providing numerous alternative treatment options
CHAPTER 8 PROSTATE CANCER
- Overview of prostate cancer
  - Definition
    - The most common cancer type and second-leading cause of cancer-related death in males
  - Epidemiology
    - Incidence of prostate cancer continues to rise with advances in screening procedures
    - Mortality from prostate cancer is relatively low given the high propensity for early diagnosis
  - Treatment of prostate cancer
- Unmet need in prostate cancer
  - Summary of unmet needs
    - Side effects from antihormonal therapies may affect compliance
    - Alternative treatment options are needed for hormone-refractory patients
    - Greater R&D interest is needed in terms of innovative therapies
- Pipeline overview
  - Pipeline summary
  - Late-phase pipeline
  - Phase II pipeline
  - Comparative forecasts
  - Definition of current comparator therapy
- Pipeline candidates
  - Avastin (bevacizumab; Genentech/Roche)
    - Drug overview
    - Key historical events
    - Clinical development in prostate cancer
    - Datamonitor comments
  - Xinlay (atrasentan; Abbott)
    - Drug overview
    - Key historical events
    - Clinical development in prostate cancer
    - Datamonitor comments
  - Abiraterone (CB-7630; Cougar Biotechnology/BTG)
    - Drug overview
    - Key historical events
    - Clinical development in prostate cancer
    - Datamonitor comments
  - Aflibercept (VEGF-Trap; Regeneron/Sanofi-Aventis)
    - Drug overview
    - Key historical events
    - Clinical development in prostate cancer
    - Datamonitor comments
  - Zibotentan (ZD-4054; AstraZeneca)
    - Drug overview
    - Key historical events
    - Clinical development in prostate cancer
    - Datamonitor comments
  - Cabazitaxel (XRP-6258; Sanofi-Aventis)
    - Drug overview
    - Key historical developments
    - Clinical development in prostate cancer
    - Datamonitor comments
  - Firmagon (degarelix; Ferring/Astellas)
    - Drug overview
    - Key historical developments
    - Clinical development in prostate cancer
    - Datamonitor comments
  - GVAX (CG-8123; Cell Genesys/Takeda)
    - Drug overview
    - Key historical events
    - Clinical development in prostate cancer
    - Datamonitor comments
  - Provenge (sipuleucel-T; Dendreon)
    - Drug overview
    - Key historical events
    - Clinical development in prostate cancer
    - Datamonitor comments
  - Tookad (padoporfin; Weizmann Institute/Steba Biotech)
    - Drug overview
    - Key historical events
    - Clinical development in prostate cancer
    - Datamonitor comments
  - Satisfaction of unmet needs
    - Superiority over current standard therapies is unlikely to be shown by the current pipeline
CHAPTER 9 RENAL CELL CARCINOMA
- Overview of renal cell carcinoma
  - Definition
    - Renal cell carcinoma has become a popular R&D indication for drug developers
  - Epidemiology
    - Incidence of renal cell carcinoma will continue to rise in line with the ageing population, increasing rates of obesity and more frequent diagnosis following imaging procedures
    - Mortality is high in late-stage RCC patients
  - Treatment of RCC
- Unmet need in RCC
  - Summary of unmet need
    - Adjuvant therapy to prevent relapse following surgery in Stage I-III patients
    - More systemic therapies required to provide options in later lines of treatment
    - Non-clear cell RCC subtypes must be the focus of future therapies
- Pipeline overview
  - Pipeline summary
  - Late-phase pipeline
  - Phase II pipeline
  - Comparative forecasts
  - Definition of current comparator therapy
- Pipeline candidates
  - Afinitor (everolimus; Novartis)
    - Drug overview
    - Key historical events
    - Clinical development in RCC
    - Datamonitor comments
  - Armala (pazopanib; GlaxoSmithKline)
    - Drug overview
    - Key historical events
    - Clinical development in RCC
    - Datamonitor comments
  - Rencarex (WX-G250; Wilex)
    - Drug overview
    - Key historical events
    - Clinical development in RCC
    - Datamonitor comments
  - Axitinib (AG-13736; Pfizer)
    - Drug overview
    - Key historical events
    - Clinical development in RCC
    - Datamonitor comments
  - Oncophage (vitespen; Antigenics)
    - Drug overview
    - Key historical events
    - Clinical development in RCC
    - Datamonitor comments
  - Reniale (LipoNova)
    - Drug overview
    - Key historical events
    - Clinical development in RCC
    - Datamonitor comments
  - TroVax (MVA-h5T4; Oxford Biomedica/Sanofi-Aventis)
    - Drug overview
    - Key historical events
    - Clinical development in RCC
    - Datamonitor comments
  - Satisfaction of unmet needs
    - Afinitor shows great promise for fulfilling unmet needs in later lines of therapy, while Rencarex and Reniale show potential in the adjuvant setting
APPENDIX A
- Bibliography
- List of tables
- List of figures
- List of abbreviations
- Contributing experts
- Methodology
  - Datamonitor forecast methodology
    - Epidemiology forecasts
    - Product forecasts
  - Datamonitor drug assessment summary
APPENDIX B
- About Datamonitor
  - About Datamonitor Healthcare
- Datamonitor Healthcare' s therapy area capabilities
  - About the Disease analysis team
  - Disclaimer
List of Tables
- Table 1: Late-phase cytotoxics pipeline for bladder cancer, breast cancer, cervical cancer, ovarian cancer, prostate cancer and RCC, 2008
- Table 2: Late-phase immunotherapies pipeline for bladder cancer, breast cancer, cervical cancer, ovarian cancer, prostate cancer and RCC, 2008
- Table 3: Late-phase endocrine and photodynamic therapies pipeline for bladder cancer, breast cancer, cervical cancer, ovarian cancer, prostate cancer and RCC, 2008
- Table 4: Late-phase targeted therapies pipeline for bladder cancer, breast cancer, cervical cancer, ovarian cancer, prostate cancer and RCC, 2008
- Table 5: Pipeline split by developmental phase and indication, 2008
- Table 6: Cytotoxic subgroup mechanisms of action
- Table 7: Antihormonal subgroup mechanisms of action
- Table 8: Targeted therapy subgroup mechanisms of action
- Table 9: Immunotherapy subgroup mechanisms of action
- Table 10: Oncology clinical trial design factors
- Table 11: Crude incidence rate of bladder cancer per 100,000 population in the seven major pharmaceutical markets, 2002
- Table 12: Forecast incidence of bladder cancer in the seven major pharmaceutical markets, 2002-2017
- Table 13: Five-year survival rates by stage of bladder cancer, 1975-2000
- Table 14: Late-phase bladder cancer pipeline, 2008
- Table 15: Phase II bladder cancer pipeline, 2008
- Table 16: Forecasting assumptions for bladder cancer pipeline products across the seven major markets, 2008 (1 of 2)
- Table 17: Forecasting assumptions for bladder cancer pipeline products across the seven major markets, 2008 (2 of 2)
- Table 18: Pipeline bladder cancer product sales forecasts across the seven major markets, 2008-2017 ($m)
- Table 19: TheraCys: key historical facts
- Table 20: Urocidin: key historical events
- Table 21: Clinical development of Urocidin in bladder cancer, 2008
- Table 22: EOquin: key historical events
- Table 23: Clinical development of EOquin in bladder cancer, 2008
- Table 24: Valstar: key historical events
- Table 25: Larotaxel: key historical events
- Table 26: Clinical development of larotaxel in bladder cancer, 2008
- Table 27: Fulfillment of unmet needs by pipeline bladder cancer drugs, 2008
- Table 28: Forecast incidence of breast cancer in the seven major pharmaceutical markets, 2002-2017
- Table 29: Eight-year survival rates by stage of breast cancer
- Table 30: Phase III breast cancer pipeline, 2008
- Table 31: Phase II breast cancer pipeline, 2008 (targeted therapies)
- Table 32: Phase II breast cancer pipeline, 2008 (cytotoxics)
- Table 33: Phase II breast cancer pipeline, 2008 (immunotherapies)
- Table 34: Phase II breast cancer pipeline, 2008 (miscellaneous)
- Table 35: Forecasting assumptions for breast cancer pipeline products across the seven major markets, 2008 (1 of 2)
- Table 36: Forecasting assumptions for breast cancer pipeline products across the seven major markets, 2008 (2 of 2)
- Table 37: Pipeline breast cancer product sales forecasts across the seven major markets, 2008-2017 ($m)
- Table 38: Taxotere: key historical facts
- Table 39: Afinitor: key historical events
- Table 40: Clinical development of Afinitor in breast cancer, 2008
- Table 41: Armala: key historical events
- Table 42: Clinical development of Armala in breast cancer, 2008
- Table 43: Omnitarg: key historical events
- Table 44: Clinical development of Omnitarg in breast cancer, 2008
- Table 45: Sutent: key historical events
- Table 46: Clinical development of Sutent in breast cancer, 2008
- Table 47: Ramucirumab: key historical events
- Table 48: Clinical development of ramucirumab in breast cancer, 2008
- Table 49: Eribulin: key historical events
- Table 50: Clinical development of eribulin in breast cancer, 2008
- Table 51: Fulfillment of unmet needs by pipeline breast cancer drugs, 2008
- Table 52: Datamonitor' s forecast incidence of cervical cancer in the seven major pharmaceutical markets, 2002-2017
- Table 53: Phase III cervical cancer pipeline, 2008
- Table 54: Phase II cervical cancer pipeline, 2008 (targeted therapies)
- Table 55: Phase II cervical cancer pipeline, 2008 (cytotoxics and immunotherapies)
- Table 56: Forecasting assumptions for pipeline cervical cancer products across the seven major markets, 2008
- Table 57: Pipeline cervical cancer product sales forecasts across the seven major markets, 2008-2017 ($m)
- Table 58: Hycamtin: key historical facts
- Table 59: Gemzar: key historical events
- Table 60: Clinical development of Gemzar in cervical cancer, 2008
- Table 61: Phase II study results investigating single-agent Gemzar in previously treated advanced cervical cancer
- Table 62: Phase II study results investigating second-line Gemzar-based combination regimens in advanced cervical cancer
- Table 63: Tirazone: key historical events
- Table 64: Clinical development of Tirazone in cervical cancer, 2008
- Table 65: Fulfillment of unmet needs by pipeline cervical cancer drugs, 2008
- Table 66: Datamonitor' s forecast incidence of ovarian cancer in the seven major pharmaceutical markets, 2002-2017
- Table 67: Stage distribution at diagnosis
- Table 68: Five-year survival rate by stage of ovarian cancer
- Table 69: Phase III ovarian cancer pipeline, 2008
- Table 70: Phase II ovarian cancer pipeline, 2008 (targeted therapies)
- Table 71: Phase II ovarian cancer pipeline, 2008 (cytotoxics)
- Table 72: Phase II ovarian cancer pipeline, 2008 (miscellaneous)
- Table 73: Forecasting assumptions for pipeline ovarian cancer products across the seven major markets, 2008 (1 of 3)
- Table 74: Forecasting assumptions for pipeline ovarian cancer products across the seven major markets, 2008 (2 of 3)
- Table 75: Forecasting assumptions for pipeline ovarian cancer products across the seven major markets, 2008 (3 of 3)
- Table 76: Pipeline ovarian cancer product sales forecasts across the seven major markets, 2008-2017 ($m)
- Table 77: Hycamtin: key historical facts
- Table 78: Avastin: key historical events
- Table 79: Clinical development of Avastin in ovarian cancer, 2008
- Table 80: Telcyta: key historical events
- Table 81: Clinical development of Telcyta in ovarian cancer, 2008
- Table 82: Phenoxodiol: key historical events
- Table 83: Clinical development of phenoxodiol in ovarian cancer, 2008
- Table 84: Karenitecin: key historical events
- Table 85: Clinical development of Karenitecin in ovarian cancer, 2008
- Table 86: Opaxio: key historical events
- Table 87: Clinical development of Opaxio in ovarian cancer, 2008
- Table 88: Yondelis: key historical events
- Table 89: Clinical development of Yondelis in ovarian cancer, 2008
- Table 90: Patupilone: key historical events
- Table 91: Clinical development of patupilone in ovarian cancer, 2008
- Table 92: Abagovomab: key historical events
- Table 93: Clinical development of abagovomab in ovarian cancer, 2008
- Table 94: Fulfillment of unmet needs by pipeline ovarian cancer drugs, 2008
- Table 95: Datamonitor' s forecast incidence of prostate cancer in the seven major pharmaceutical markets, 2002-2017
- Table 96: Late-phase prostate cancer pipeline, 2008
- Table 97: Phase II prostate cancer pipeline, 2008 (targeted therapies)
- Table 98: Phase II prostate cancer pipeline, 2008 (cytotoxics)
- Table 99: Phase II prostate cancer pipeline, 2008 (immunotherapies)
- Table 100: Phase II prostate cancer pipeline, 2008 (miscellaneous)
- Table 101: Forecasting assumptions for pipeline prostate cancer products across the seven major markets, 2008 (1 of 3)
- Table 102: Forecasting assumptions for pipeline prostate cancer products across the seven major markets, 2008 (2 of 3)
- Table 103: Forecasting assumptions for pipeline prostate cancer products across the seven major markets, 2008 (3 of 3)
- Table 104: Pipeline prostate cancer product sales forecasts across the seven major markets, 2008-2017 ($m)
- Table 105: Taxotere: key historical facts
- Table 106: Avastin: key historical events
- Table 107: Clinical development of Avastin in prostate cancer, 2008
- Table 108: Xinlay: key historical events
- Table 109: Clinical development of Xinlay in prostate cancer, 2008
- Table 110: Abiraterone: key historical events
- Table 111: Clinical development of abiraterone in prostate cancer, 2008
- Table 112: Aflibercept: key historical events
- Table 113: Clinical development of aflibercept in prostate cancer, 2008
- Table 114: Zibotentan: key historical events
- Table 115: Clinical development of zibotentan in prostate cancer, 2008
- Table 116: Cabazitaxel: key historical events
- Table 117: Clinical development of cabazitaxel in prostate cancer, 2008
- Table 118: Firmagon: key historical events
- Table 119: Clinical development of Firmagon in prostate cancer, 2008
- Table 120: GVAX: key historical events
- Table 121: Clinical development of GVAX in prostate cancer, 2008
- Table 122: Phase II results for GVAX monotherapy in HRPC
- Table 123: Provenge: key historical events
- Table 124: Clinical development of Provenge in prostate cancer, 2008
- Table 125: Tookad: key historical events
- Table 126: Clinical development of Provenge in prostate cancer, 2008
- Table 127: Fulfillment of unmet needs by pipeline prostate cancer drugs, 2008
- Table 128: Datamonitor' s forecast incidence of RCC in the seven major pharmaceutical markets, 2002-2017
- Table 129: Five-year survival rate by stage of RCC, 2004
- Table 130: Stage of RCC at diagnosis
- Table 131: Phase III RCC pipeline, 2008
- Table 132: Phase II RCC pipeline, 2008 (targeted therapies)
- Table 133: Phase II RCC pipeline, 2008 (immunotherapies)
- Table 134: Phase II RCC pipeline, 2008 (cytotoxics)
- Table 135: Forecasting assumptions for pipeline RCC products across the seven major markets, 2008 (1 of 2)
- Table 136: Forecasting assumptions for pipeline RCC products across the seven major markets, 2008 (2 of 2)
- Table 137: Pipeline RCC product sales forecasts across the seven major markets, 2008-2017 ($m)
- Table 138: Sutent: key facts
- Table 139: Afinitor: key historical events
- Table 140: Clinical development of Afinitor in RCC, 2008
- Table 141: Armala: key historical events
- Table 142: Clinical development of Armala in RCC, 2008
- Table 143: Rencarex: key historical events
- Table 144: Clinical development of Rencarex in RCC, 2008
- Table 145: Axitinib: key historical events
- Table 146: Clinical development of axitinib in RCC, 2008
- Table 147: Oncophage: key historical events
- Table 148: Reniale: key historical events
- Table 149: TroVax: key historical events
- Table 150: Clinical development of TroVax in RCC, 2008
- Table 151: Fulfillment of unmet needs by pipeline RCC drugs, 2008
- Table 152: List of abbreviations
- Table 153: Datamonitor drug assessment parameters
List of Figures
- Figure 1: Forecast incidence and mortality from bladder cancer in 2008 and 2017 across the seven major markets
- Figure 2: Summary of unmet needs in the bladder cancer market, 2008
- Figure 3: Datamonitor drug assessment summary for the pipeline bladder cancer products, 2008
- Figure 4: Pipeline bladder cancer product sales forecasts across the seven major markets, 2008-2017 ($m)
- Figure 5: Phase II study investigating Urocidin in high-risk superficial bladder cancer
- Figure 6: Phase II study investigating EOquin in recurrent non-invasive bladder cancer
- Figure 7: Forecast incidence and mortality from breast cancer in 2008 and 2017 across the seven major markets
- Figure 8: Summary of unmet needs in the breast cancer market, 2008
- Figure 9: Datamonitor drug assessment summary for the pipeline breast cancer products, 2008
- Figure 10: Pipeline breast cancer product sales forecasts across the seven major markets, 2008-2017 ($m)
- Figure 11: Phase II trial results investigating neoadjuvant Afinitor plus Femara in hormone receptor-positive breast cancer
- Figure 12: Phase II results investigating first/second-line Afinitor monotherapy in metastatic breast cancer
- Figure 13: Phase II results investigating first-line Tykerb with or without Armala in HER-2-positive advanced or metastatic breast cancer
- Figure 14: Phase II results investigating Omnitarg plus Herceptin in HER-2-positive metastatic breast cancer following failure of prior Herceptin
- Figure 15: Phase II results investigating single-agent Omnitarg metastatic breast cancer with low HER-2 expression
- Figure 16: Phase II results investigating single-agent Sutent in previously treated metastatic breast cancer
- patients
- Figure 18: Phase II study investigating third-line or higher eribulin in chemotherapy-refractory advanced breast cancer patients
- Figure 19: Incidence and mortality from cervical cancer in 2008 and 2017 across the seven major markets
- Figure 20: Summary of unmet needs in the cervical cancer market, 2008
- Figure 21: Datamonitor drug assessment summary for the pipeline cervical cancer products, 2008
- Figure 22: Pipeline cervical cancer product sales forecasts across the seven major markets, 2008-2017 ($m)
- Figure 23: Phase II trial investigating first/second-line Tirazone and cisplatin in metastatic cervical cancer patients (Maluf study)
- Figure 24: Phase II trial investigating first-line Tirazone and cisplatin in metastatic cervical cancer patients
- Figure 25: Incidence and mortality from ovarian cancer in 2008 and 2017 across the seven major markets
- Figure 26: Summary of unmet needs in the ovarian cancer market, 2008
- Figure 27: Datamonitor drug assessment summary for the pipeline ovarian cancer products, 2008
- Figure 28: Pipeline ovarian cancer product sales forecasts across the seven major markets, 2008-2017 ($m)
- Figure 29: Phase II trial investigating Avastin monotherapy or combination chemotherapy regimens in heavily pretreated ovarian cancer
- Figure 30: Phase II trial investigating third-line Avastin and Hycamtin in platinum-refractory recurrent ovarian cancer
- Figure 31: Phase II trial investigating first-line Avastin, cisplatin and paclitaxel in optimally debulked Stage II/III ovarian cancer
- Figure 32: Phase III ASSIST-1 study comparing third-line Telcyta with Doxil or Hycamtin
- Figure 33: Phase III ASSIST-3 study comparing second-line Telcyta + carboplatin with Doxil
- Figure 34: Preliminary Phase IIa results investigating a second-line combination of phenoxodiol with either paclitaxel or cisplatin
Figure 35: Phase II results investigating third-line Karenitecin in recurrent or persistent ovarian cancer
- Figure 36: Phase II trial results investigating Opaxio in newly diagnosed Stage III/IV ovarian cancer patients
- Figure 37: Pooled results from three Phase II trials investigating Yondelis in advanced relapsed ovarian cancer
- Figure 38: Phase I/II trial investigating second-line patupilone in refractory or relapsed advanced ovarian cancer
- Figure 39: Phase I/II trial investigating maintenance abagovomab following chemotherapy for recurrent ovarian cancer
- Figure 40: Incidence and mortality from prostate cancer in 2008 and 2017 across the seven major markets
- Figure 41: Summary of unmet needs in the prostate cancer market, 2008
- Figure 42: Datamonitor drug assessment summary for the pipeline prostate cancer products, 2008
- Figure 43: Pipeline prostate cancer product sales forecasts across the seven major markets, 2008-2017 ($m)
- Figure 44: Initial Phase II results investigating first-line Avastin, Taxotere and estramustine in metastatic HRPC
- Figure 45: Phase II results investigating first-line Avastin, Taxotere and Thalomid in metastatic HRPC
- Figure 46: Meta-analysis of pooled data from the M96-594 and M00-211 clinical trials in metastatic HRPC
- Figure 47: Phase III M00-244 study results in non-metastatic HRPC
- Figure 48: Preliminary Phase II COU-AA-004 results for second/third-line abiraterone and prednisone in advanced HRPC
- Figure 49: Combined COU-AA-001 Phase I/II and COU-AA-003 Phase II results in chemotherapy-naïve patients and taxane-pretreated patients
- Figure 50: Phase II study investigating first-line zibotentan in HRPC metastatic to the bone
- Figure 51: Phase III CS21 study results comparing Firmagon to Lupron in hormone-sensitive prostate cancer
- Figure 52: Phase III D9901 results investigating Provenge in asymptomatic metastatic HRPC
- Figure 53: Analysis of patient subgroup from Phase III D9901 and D9902A studies who received Taxotere following Provenge or placebo
- Figure 54: Phase III PROTECT results investigating Provenge in hormone-sensitive non-metastatic prostate cancer
- Figure 55: Incidence and mortality from RCC in 2008 and 2017 across the seven major markets
- Figure 56: Summary of unmet needs in the RCC market, 2008
- Figure 57: Datamonitor drug assessment summary for the pipeline RCC cancer products, 2008
- Figure 58: Pipeline RCC product sales forecasts across the seven major markets, 2008-2017 ($m)
- Figure 59: Phase III RECORD-1 trial results investigating Afinitor in tyrosine kinase inhibitor-refractory metastatic RCC
- Figure 60: Final analysis of a Phase II trial investigating single-agent Armala in cytokine-naïve and refractory patients
- Figure 61: Phase II results for Rencarex monotherapy in metastatic RCC
- Figure 62: Phase II results for Rencarex and interferon-alfa in metastatic RCC
- Figure 63: Phase II results for axitinib in RCC patients refractory to Sutent, Nexavar and/or cytokine therapy
- Figure 64: Phase III trial data investigating adjuvant Reniale
- Figure 65: Datamonitor drug assessment summary of pipeline molecular targeted therapies in development for hematological malignancies, 2007

Pipeline Insight: Cancer Overview - Breast, Gynecological, Genitourinary - Diverse drugs approaching the market for many tumor types

Table of Contents